Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Janet Lensing"'
Publikováno v:
Insects, Vol 14, Iss 4, p 372 (2023)
Since their introduction into the United States in the early 1900′s, imported fire ants, namely Solenopsis invicta Buren (Red Imported Fire Ant), S. richteri Forel (Black Imported Fire Ant), and their hybrid form Solenopsis invicta X richteri have
Externí odkaz:
https://doaj.org/article/45afb696e4a643008801749b663e9c9f
Autor:
Dale Miles, Millie Das, Branimir I. Sikic, Adam Frymoyer, Heather A. Wakelee, Sukhmani K. Padda, Alex A. Adjei, Janet Lensing, Julian R. Molina
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:541-550
To evaluate the safety, tolerability, and pharmacokinetics of XL647 and determine the maximum tolerated dose (MTD) of oral XL647 once-daily using intermittent or continuous dosing schedules. Patients with advanced solid malignancies were enrolled in
Autor:
Kyriakos P. Papadopoulos, Sameera R. Wijayawardana, Palaniappan Kulanthaivel, Rebecca Arcos, Louis Stancato, Claudia S. Kelly, Drew W. Rasco, Charles Erlichman, Janet Lensing, Peipei Shi, Matthew P. Goetz, Robert Bell, Anthony W. Tolcher, Julian R. Molina, Paul Haluska, Lynette B. Mulle, Amita Patnaik, Daphne L. Farrington, Edward M. Chan, Celine Pitou, Xuekui Zhang, Muralidhar Beeram
Publikováno v:
Clinical Cancer Research. 22:1095-1102
Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective
Autor:
Janet Lensing, Charles Erlichman, Suneetha Puttabasavaiah, Joleen M. Hubbard, Elizabeth Johnson, Mitesh J. Borad, Rui Qin, George P. Kim, John Wright, Axel Grothey
Publikováno v:
Investigational New Drugs. 34:96-103
Background A previous phase II trial in patients with chemorefractory metastatic colorectal cancer demonstrated a 63 % disease control rate with a combination of bevacizumab and sorafenib. This phase I trial sought to determine the maximum tolerable
Autor:
Guy G. Poirer, Michael E. Menefee, Paul Haluska, Maria I. Harrell, Joel M. Reid, Donald W. Northfelt, Jiuping Ji, Janet Lensing, Charles Erlichman, Andrea E. Wahner Hendrickson, Karen S. Flatten, Scott H. Kaufmann, Lynn C. Hartmann, Yiping Zang, Felix Boakye-Agyeman, Daniel Satele, Harry J. Long, Elizabeth M. Swisher, Olumide Kayode, Alice P. Chen, Jake Allred
Publikováno v:
Clin Cancer Res
Purpose: To determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess
Autor:
Joel M. Reid, Scott H. Kaufmann, Jake Allred, J. Lea, V. Kennedy, A.E. Wahner Hendrickson, Daniel Satele, B. Corr, Elizabeth M. Swisher, Araba A. Adjei, Brian A. Costello, Gini F. Fleming, Sarah Taylor, Charles Erlichman, S. P. Ivy, Janet Lensing, A. Jewell
Publikováno v:
Annals of Oncology. 29:viii357
Autor:
Andrea E. Wahner Hendrickson, Michael E. Menefee, Harry J. Long, Karen S. Flatten, Fleix Boakye-Agyeman, Donald W. Northfelt, Janet Lensing, Paul Haluska, Lynn C. Hartmann, Scott H. Kaufmann, Charles Erlichman, Joel M. Reid, Guy G. Poirier
Publikováno v:
Journal of Clinical Oncology. 33:TPS2618-TPS2618
TPS2618 Background: PARPs are a highly conserved family of enzymes whose predominant function is to preserve genomic integrity following DNA damage. Preclinical studies demonstrated that PARP inhib...
Autor:
Crescent R. Isham, Jeff A. Sloan, Matthew M. Ames, Alex A. Adjei, Scott H. Kaufmann, Stacie L. Rubin, Jill Piens, Pamela J. Atherton, Keith C. Bible, Michelle K. Daiss, Janet Lensing, Sacha A. Nelson, Charles Erlichman, Joseph Rubin, Joel M. Reid, Yean K. Lee
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(16)
Purpose: Flavopiridol, a cyclin-dependent kinase inhibitor, transcription inhibitor, and DNA-interacting agent, was combined with cisplatin or carboplatin to establish toxicities, evaluate pharmacokinetics, and examine its effects on patient cancers
Autor:
Axel Grothey, George P. Kim, Janet Lensing, John Wright, Charles Erlichman, Mitesh J. Borad, Rui Qin, Joleen M. Hubbard
Publikováno v:
Journal of Clinical Oncology. 32:551-551
551 Background: Sorafenib inhibits various pro-angiogenesis pathways including PDGFR-B, a factor associated with resistance to anti-VEGF therapy. A previous phase II trial in patients with chemorefractory metastatic CRC demonstrated a 63% disease con
Autor:
Celine Pitou, Kyriakos P. Papadopoulos, Janet Lensing, Matthew P. Goetz, Charles Erlichman, Rebecca Arcos, Lynette B. Mulle, Peipei Shi, Anthony W. Tolcher, Palaniappan Kulanthaivel, Drew W. Rasco, Edward M. Chan, Julian R. Molina, Muralidhar Beeram, Paul Haluska, Amita Patnaik
Publikováno v:
Journal of Clinical Oncology. 30:3001-3001
3001 Background: p38 MAPK regulates production of cytokines by the tumor microenvironment and its activation enables cancer cells to survive in the presence of oncogenic stress, radiation, chemotherapy, and targeted therapies. LY2228820 is a selectiv